Clinical Data ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide sustains weight loss long term Pharmaceutical TechnologyAt ECO 2026, data from the SURMOUNT-MAINTAIN trial evaluating the use of Eli Lilly's Zepbound (tirzepatide) in sustaining weight loss was presented.Metabolic & GLP-1Read full story pharminent May 15, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology At ECO 2026, data from the SURMOUNT-MAINTAIN trial evaluating the use of Eli Lilly’s Zepbound (tirzepatide) in sustaining weight loss was presented. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Trial miss doesn’t dent Biogen’s faith in Alzheimer’s drugNext: Kyowa Kirin secures FDA approval for Crysvita dosing update Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
